Andesa Financial Management Inc. acquired a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) during the 1st quarter, HoldingsChannel.com reports. The fund acquired 339 shares of the biopharmaceutical company’s stock, valued at approximately $236,000.
A number of other institutional investors have also recently added to or reduced their stakes in REGN. BlackRock Inc. increased its stake in shares of Regeneron Pharmaceuticals by 2.6% during the 4th quarter. BlackRock Inc. now owns 9,610,871 shares of the biopharmaceutical company’s stock worth $6,069,457,000 after purchasing an additional 244,009 shares during the last quarter. State Street Corp lifted its position in shares of Regeneron Pharmaceuticals by 3.4% in the fourth quarter. State Street Corp now owns 4,799,822 shares of the biopharmaceutical company’s stock worth $3,031,184,000 after buying an additional 159,817 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Regeneron Pharmaceuticals by 11.9% during the 4th quarter. JPMorgan Chase & Co. now owns 4,591,529 shares of the biopharmaceutical company’s stock worth $2,899,642,000 after acquiring an additional 489,084 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 13.6% during the 4th quarter. Geode Capital Management LLC now owns 1,977,302 shares of the biopharmaceutical company’s stock worth $1,245,725,000 after acquiring an additional 237,090 shares in the last quarter. Finally, Northern Trust Corp raised its stake in shares of Regeneron Pharmaceuticals by 0.3% in the 4th quarter. Northern Trust Corp now owns 1,203,326 shares of the biopharmaceutical company’s stock valued at $759,925,000 after acquiring an additional 3,291 shares in the last quarter. 83.83% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling at Regeneron Pharmaceuticals
In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,100 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, August 1st. The stock was sold at an average price of $581.53, for a total transaction of $639,683.00. Following the completion of the transaction, the executive vice president now directly owns 19,644 shares of the company’s stock, valued at $11,423,575.32. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 8.99% of the company’s stock.
Analyst Upgrades and Downgrades
Regeneron Pharmaceuticals Price Performance
Shares of Regeneron Pharmaceuticals stock opened at $613.61 on Friday. The firm has a market cap of $66.60 billion, a P/E ratio of 12.25, a price-to-earnings-growth ratio of 1.88 and a beta of 0.29. The firm’s 50-day simple moving average is $598.47 and its 200-day simple moving average is $635.98. Regeneron Pharmaceuticals, Inc. has a twelve month low of $538.01 and a twelve month high of $747.42. The company has a debt-to-equity ratio of 0.13, a quick ratio of 4.09 and a current ratio of 5.12.
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Rating) last released its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported $9.77 earnings per share for the quarter, missing the consensus estimate of $9.94 by ($0.17). Regeneron Pharmaceuticals had a net margin of 39.97% and a return on equity of 36.17%. The company had revenue of $2.86 billion during the quarter, compared to the consensus estimate of $2.80 billion. During the same quarter in the prior year, the company posted $27.97 earnings per share. The company’s revenue for the quarter was down 44.4% on a year-over-year basis. As a group, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 40.89 EPS for the current fiscal year.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
- Get a free copy of the StockNews.com research report on Regeneron Pharmaceuticals (REGN)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.